Injectable Collagenase Versus Percutaneous Needle Fasciotomy for Dupuytren Contracture in Proximal Interphalangeal Joints: A Randomized Controlled Trial

This report has been verified by one or more authors of the original publication.

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

50 patients with Dupuytren’s contracture were randomized to treatment with either collagenase clostridium histolyticum injection or percutaneous needle fasciotomy. Patients were assessed for rates of clinical improvement, clinical success, recurrence, and adverse events at 30 days, 1-year, and 2 years after treatment. Both groups demonstrated an early 30-day clinical improvement, however, the rate of clinical improvements and success in both groups declined at 1 and 2 years. There were no significant differences between groups in clinical improvement or success over the 2-year follow-up. The recurrence rate at 2 years was 83% in the collagenase group and 68% in the fasciotomy group. Collagenase injections were associated with significantly higher rates of edema and local pain after treatment in comparison to needle fasciotomy.